Evaluation of Xpert HIV-Qual assay for resolution of HIV-infection in samples with negative or indeterminate Geenius HIV-1/2 results

Michal Michaeli, Marina Wax, Yael Gozlan, Aviya Rakovsky, Ella Mendelson, Orna Mor

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Background: Diagnosis of HIV infection is a multistage algorithm. Following screening with 4th generation combination immunoassay, confirmation of HIV infection is performed with an antibody assay that differentiates HIV-from HIV-infection. In the newly updated algorithm, samples that are nonreactive or indeterminate in the differentiation assay are to be tested with an HIV-nucleic acid amplification (NAAT) test for resolution. Xpert HIV-Qual is a new NAAT assay approved for the identification of HIV infection in whole and dried blood. Objectives: To assess the performance of Xpert HIV-Qual supplementary assay in resolving the clinical status of serum samples reactive by 4th generation immunoassays and indeterminate or negative by Geenius HIV-1/2 confirmatory assay. Study design: In a retrospective study, samples from 97 individuals for whom the true HIV-status was already known (by follow-up samples) and which were negative or indeterminate by HIV-1/2 Geenius assay were tested with Xpert Qual HIV-assay. Results: Xpert Qual assay correctly classified all 97 samples from HIV-positive (n = 49) and negative (n = 48) individuals. The sensitivity and specificity of Xpert Qual when using the true HIV status as a reference were 100% (92.7-100% at 95% confidence interval [CI] and 92.6-100% at 95% CI, respectively). Conclusions: Applying Xpert Qual HIV-assay in the new HIV multi-stage diagnostic algorithm correctly classified 100% of HIV-infections including 49 from HIV-carriers who have not yet seroconverted. With this assay the total time required for acute HIV diagnosis could be significantly reduced.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalJournal of Clinical Virology
Volume76
DOIs
StatePublished - 1 Mar 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Elsevier B.V.

Funding

The authors would like to thank Mr. Boaz Rozenfeld from Medison Pharma, Israel (representatives of Cepheid) for his excellent technical support and Fabrice Magnino from Cepheid for providing the Xpert HIV-1 Qual assay free of charge.

FundersFunder number
Medison Pharma

    Keywords

    • Geenius
    • HIV-1/2 infection
    • HIV-Qual
    • NAAT
    • Xpert

    Fingerprint

    Dive into the research topics of 'Evaluation of Xpert HIV-Qual assay for resolution of HIV-infection in samples with negative or indeterminate Geenius HIV-1/2 results'. Together they form a unique fingerprint.

    Cite this